Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Emergence Therapeutics | 2021 | Series A | $98.1M | Duisburg |
| Curie Therapeutics | 2021 | Series A | $75.0M | Boston |
| Sydnexis | 2021 | Series B | $45.0M | Del Mar |
| T-knife | 2021 | Series B | $110.0M | Berlin |
| Imara | 2021 | Post Ipo Equity | $50.0M | Cambridge |
| Bolt Biotherapeutics | 2021 | Post Ipo Equity | $15.0M | Redwood City |
| NiKang Therapeutics | 2021 | Series C | $200.0M | Wilmington |
| New Equilibrium Biosciences | 2021 | Seed | $10.0M | Cambridge |
| Graphite Bio | 2021 | Series B | $150.7M | South San Francisco |
| DTx Pharma | 2021 | Series B | $100.0M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 401 | Emergence Therapeutics | Series A | $98.1M | Duisburg, Germany |
| 402 | Curie Therapeutics | Series A | $75.0M | Boston, United States |
| 403 | Sydnexis | Series B | $45.0M | Del Mar, United States |
| 404 | T-knife | Series B | $110.0M | Berlin, Germany |
| 405 | Imara | Post Ipo Equity | $50.0M | Cambridge, United States |
| 406 | Bolt Biotherapeutics | Post Ipo Equity | $15.0M | Redwood City, United States |
| 407 | NiKang Therapeutics | Series C | $200.0M | Wilmington, United States |
| 408 | New Equilibrium Biosciences | Seed | $10.0M | Cambridge, United States |
| 409 | Graphite Bio | Series B | $150.7M | South San Francisco, United States |
| 410 | DTx Pharma | Series B | $100.0M | San Diego, United States |
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
New Equilibrium Biosciences provides a platform that reveals opportunities for structure-based design by learning biophysics with AI.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Kira Pharmaceuticals is a Biotechnology Research Company.
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
PMV Pharmaceuticals is a developer of p53-targeted small molecule drugs for the treatment of cancer.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Akouos is a biotechnology company focusing on restoring and preserving hearing.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
RA Capital Management has invested in 439 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 15 different industry categories.
Among tracked funding rounds, LianBio received $310.0M in a Series A round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 439 companies.
Recent RA Capital Management portfolio additions include Emergence Therapeutics, Curie Therapeutics, Sydnexis, T-knife, Imara. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors